Ipca Laboratories Ltd Forensic Report - SOIC x StockScans Report

as of Jul 2026

Ipca Laboratories carries a disclosed and audited record with consistent cash conversion, but three things demand attention: a €13.96 million EU competition fine upheld by the highest court, a pattern of goodwill and investment impairments that continued into FY26, and a multi-year funding relationship with a loss-making associate now largely written off and headed for amalgamation.

Key findings

  1. A loss-making associate was funded through loans, equity, and collateral now largely impaired, with intermediary funding disclosures adding complexity Major - A loan of ₹48.06 crores to associate Krebs Biochemicals is overdue more than 90 days as of FY2025-26, and the full ₹13.06 crores of accrued interest has been provided for. The company took an exceptional impairment of ₹108.54 crores on its Krebs exposure in FY2024-25 and has maintained a lien on its own ₹11.00 crore term deposit to secure Krebs' credit facility from FY2020-21 through FY2025-26. Standalone FY2025-26 statements disclose funds loaned through intermediaries and later replenished from money received on specific dates.
  2. Serial acquisitions have created a multi-layered structure of 17+ entities, with several loss-making or written-off associates and subsidiaries Minor - Unichem Laboratories became a subsidiary in FY2023-24 for ₹1,542.85 crores, adding six step-down subsidiaries across the UK, South Africa, Brazil, USA, Ireland, and China. Krebs Biochemicals had negative net worth attributable of ₹59.19 crores as of March 2024, and Synchron Research Services had negative net worth of ₹0.67 crores. Bayshore Pharmaceuticals sold its ANDAs and distribution business for USD 12.65 million and was sold to an unrelated party on 13 January 2026; Niche Generics decided to close its Ireland facility due to persistent losses.
  3. Audit opinions are consistently unqualified, but the audit-trail edit-log has a persistent exception and the consolidated audit relies on other auditors for a material subsidiary Minor - In FY2026, the standalone auditor reported that the audit trail for direct database changes by the DBA is retained only for three days, and the trail prior to November 24, 2024 is unavailable. In FY2025 the same changes were not captured at all, and in FY2024 the trail was not enabled for certain access rights. The consolidated audit for FY2026 covers one material subsidiary, Unichem, with assets of ₹3,737.73 crores audited by other auditors, and two immaterial subsidiaries that were management-certified and unaudited.
  4. Promoter family holds three of four executive board seats, their re-appointments attract material dissent, and shareholders rejected two ESOP schemes Minor - The board has four executive directors, three of whom are related members of the Godha family. The re-appointment of Prashant Godha at the 12 Aug 2025 AGM drew 8.5% votes against from public shareholders, with public institutions voting 17.41% against; at the 3 Sep 2021 AGM the same resolution drew 15.51% public dissent and 34.87% institutional dissent. Shareholders defeated the Ipca ESOS 2023 scheme with 31.16% votes against, and the ESOS 2024 postal ballot resolution also failed.
  5. Operating cash flow consistently covers reported profit, though free cash flow remains modest relative to PAT Clean - Cumulative CFO of ₹7,854 crore covered 69% of cumulative EBITDA of ₹11,306 crore over the ten years to FY26. Annual CFO/PAT ranged from 0.94x to 1.79x over FY21-FY26, standing at 0.96x in FY26. Free cash flow was ₹486 crore in FY26, and ROCE improved from 10.80% in FY23 to 18.58% in FY26.
  6. Statutory auditor changed in FY2022-23; subsidiary fees were minor Clean - The auditor changed from G.M. Kapadia & Co. to Natvarlal Vepari & Co. at the 72nd AGM in FY2022-23, appointed for a five-year term ending in 2027. The firm changed its name to N V C & Associates LLP by FY2025-26, with partner N. Jayendran signing across all three years. Subsidiary fees to the auditor network were ₹6.10 lacs and ₹1.42 lacs in FY2024-25, and ₹5.25 lacs and ₹1.66 lacs in FY2025-26.

What to watch

Bottom line: This is a disclosed and audited record with operating cash flow that consistently covers profit and a clean audit opinion history. The risk sits in three places: the EU competition fine now upheld by the highest court, a pattern of acquisition-related impairments that continued into FY26, and the Krebs exposure now headed for amalgamation after years of funding and write-downs. Watch the Krebs scheme outcome, the Pisgah commercialization timeline, and whether the audit-trail exception is resolved.